BeiGene raises $903m in HK’s first secondary listing under new rules

Visual from website of Refuge Biotechnologies

Chinese Nasdaq-listed biotech BeiGene Ltd has raised $903 million after pricing its secondary listing in Hong Kong – the first under new exchange rules – near the top of an indicative range, three people close to the deal said on Thursday.

Continue reading this story with a subscription to DealStreetAsia.

Subscribe

Contact us for corporate subscriptions at subs@dealstreetasia.com.